Yupelri Side Effects, Warnings, and COPD Use

Yupelri side effects are usually mild and can include cough, upper respiratory symptoms, headache and back pain, but some people may experience more serious effects such as sudden worsening of breathing, eye symptoms or urinary retention. Yupelri is a prescription maintenance medicine for chronic obstructive pulmonary disease (COPD), not a fast-acting rescue treatment for sudden breathing symptoms.

Yupelri at a glance

Yupelri is the brand name for revefenacin, an inhaled prescription medicine used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). COPD is a group of progressive lung conditions, including chronic bronchitis and emphysema, that can make it harder to move air in and out of the lungs. Yupelri helps keep the airways more open over time, which may support easier breathing as part of an individualized COPD treatment plan.

Yupelri belongs to a medicine class called long-acting muscarinic antagonists, also known as LAMAs or long-acting anticholinergics. It is supplied as an inhalation solution and is intended to be used with a standard jet nebulizer. A nebulizer changes liquid medicine into a mist that is inhaled through a mouthpiece.

This medicine is not a rescue medication. It does not work quickly enough to treat sudden breathing difficulty, a sudden COPD flare-up or acute bronchospasm. A clinician may prescribe a separate short-acting rescue inhaler for sudden symptoms. Yupelri is not indicated for the treatment of asthma.

Yupelri side effects: common and serious

In clinical trials, the most commonly reported Yupelri side effects included cough, nasopharyngitis (cold-like irritation or inflammation of the nose and throat), upper respiratory tract infection, headache and back pain. Not every symptom that occurs during treatment is caused by a medicine, but new, persistent or troubling symptoms should be discussed with the prescribing clinician.

Because Yupelri has anticholinergic effects, it can occasionally cause effects related to the eyes or urinary tract. It may worsen narrow-angle glaucoma or urinary retention in susceptible people. Symptoms that deserve prompt medical advice include eye pain or discomfort, blurred vision, seeing halos or colored images around lights, difficulty starting urination, weak urine flow, or painful urination.

Rarely, inhaled medicines can cause paradoxical bronchospasm, meaning breathing suddenly becomes more difficult immediately after use. This can be serious and requires stopping the medicine and seeking urgent medical assessment. Signs of a severe allergic reaction, such as swelling of the face, lips, tongue or throat, hives, rash, or trouble breathing, also require urgent care.

• Commonly reported effects: cough, cold-like symptoms, upper respiratory infection, headache and back pain.
• Potential anticholinergic effects: dry mouth, eye-related symptoms or urinary difficulties may occur.
• Urgent concerns: sudden wheezing after inhalation, severe shortness of breath, or signs of an allergic reaction.

How Yupelri works and who it is for

Revefenacin works by blocking muscarinic receptors in the airway muscles. These receptors are involved in airway tightening. By reducing this tightening, Yupelri helps relax the muscles around the bronchi, the larger breathing tubes in the lungs. This bronchodilator effect is designed to support ongoing symptom control rather than immediate relief.

Yupelri is approved for maintenance treatment of COPD in adults. COPD care usually involves more than one medicine decision. Clinicians consider a person’s symptoms, exacerbation history, inhaler or nebulizer technique, smoking status, other health conditions and current medicines. Pulmonary rehabilitation, vaccination, physical activity when appropriate and smoking cessation can also be important parts of care.

People with COPD may have daily symptoms such as breathlessness with activity, cough, mucus production or reduced exercise tolerance. However, sudden changes in these symptoms can signal an exacerbation or another health issue. It is important not to rely on Yupelri alone for a sudden change in breathing. More information about the underlying condition is available in this overview of chronic obstructive pulmonary disease.

Dosage and how Yupelri is administered

According to the United States prescribing information, Yupelri is administered once daily as a 175 microgram inhalation solution through a standard jet nebulizer connected to an air compressor. The unit-dose vial is intended for nebulized inhalation only. It should not be swallowed, injected or used in another type of delivery device unless a clinician or pharmacist specifically confirms that it is appropriate.

Patients should follow the instructions provided with the nebulizer system and the medicine packaging. Correct use and cleaning of nebulizer equipment are important for reliable treatment delivery and to reduce contamination. A pharmacist, respiratory therapist, nurse or prescribing clinician can demonstrate the steps and check a patient’s technique.

The prescribed amount and schedule should not be changed without professional guidance. If a dose is missed, patients should ask their pharmacist or clinician how to proceed rather than taking extra medicine. People should also ensure they have an agreed action plan and access to the rescue medicine their clinician has recommended for sudden breathing symptoms.

Warnings, precautions and interactions

Yupelri is contraindicated in people with hypersensitivity to revefenacin or any component of the product. Anyone who has developed an allergic reaction after using Yupelri should not restart it without medical direction. Before beginning treatment, patients should tell their clinician about medication allergies and any past reactions to inhaled medicines.

Caution is appropriate for people with narrow-angle glaucoma or urinary retention, including urinary difficulties related to prostate enlargement or bladder obstruction. Anticholinergic medicines can worsen these conditions. Individuals with moderate or severe kidney impairment may have greater exposure to revefenacin or its active metabolite and should be monitored for anticholinergic side effects. The prescribing information does not recommend Yupelri for people with severe liver impairment.

Yupelri should generally not be used with other medicines containing anticholinergic drugs unless a clinician determines the combination is necessary. Combining medicines with similar effects can increase the risk of dry mouth, constipation, blurred vision, glaucoma-related symptoms or urinary retention. The prescribing information also advises avoiding medicines that inhibit both OATP1B1 and OATP1B3 transporters, as these may increase exposure to revefenacin.

Patients should provide a complete medication list, including inhalers, nebulizer solutions, over-the-counter products, supplements and herbal remedies. A clinician or pharmacist can identify possible interactions and decide whether an alternative treatment or closer monitoring is needed.

Using Yupelri safely in daily life

Yupelri is intended as one element of a broader COPD plan. It is helpful to keep an updated list of medicines, know the difference between maintenance and rescue treatments, and use the nebulizer exactly as instructed. If symptoms are not controlled, patients should contact their clinician rather than increasing the amount or frequency of Yupelri on their own.

Smoking cessation is one of the most meaningful steps for people who smoke and have COPD. Avoiding tobacco smoke, dust, fumes and other known airway irritants may also help reduce symptoms. Regular follow-up enables the care team to review breathing symptoms, flare-ups, treatment technique and possible side effects.

Vaccinations recommended by a clinician, including influenza and pneumococcal vaccination where appropriate, can help lower the risk of some respiratory infections. For people who are medically stable, guided activity and pulmonary rehabilitation may improve day-to-day function and confidence with breathlessness. These measures do not replace prescribed medicines, but they can complement them.

When to seek medical care

Emergency medical care is needed for severe or rapidly worsening shortness of breath, bluish lips or face, confusion, fainting, chest pain, swelling of the face or throat, or breathing that worsens immediately after using Yupelri. A rescue medicine should be used only as directed in the individual’s COPD action plan while urgent help is being arranged.

Patients should contact their clinician promptly if they need their rescue inhaler more often than usual, notice a sustained increase in cough, mucus or breathlessness, develop fever with worsening respiratory symptoms, or experience repeated COPD flare-ups. These changes may mean the COPD plan needs reassessment or that another illness is present.

Prompt medical advice is also appropriate for blurred vision, eye pain, halos around lights, difficulty urinating or a suspected medication reaction. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis and treatment planning for international patients with COPD and other respiratory conditions.

Frequently asked questions

What are the most common Yupelri side effects?

The most commonly reported Yupelri side effects include cough, nasopharyngitis, upper respiratory tract infection, headache and back pain. Some people may also experience anticholinergic effects, such as dry mouth or urinary symptoms. A clinician should assess symptoms that are persistent, severe or concerning.

Is Yupelri a rescue medicine for sudden shortness of breath?

No. Yupelri is a maintenance medicine for COPD and is not intended to treat sudden breathing problems or acute bronchospasm. Patients should use the rescue medicine prescribed by their clinician for sudden symptoms and seek urgent help for severe breathing difficulty.

Can Yupelri make breathing worse?

Rarely, Yupelri can cause paradoxical bronchospasm, in which wheezing or shortness of breath starts or worsens immediately after inhalation. This is potentially serious. The medicine should be stopped and urgent medical care sought if this occurs.

Who should use caution with Yupelri?

People with narrow-angle glaucoma, urinary retention, bladder outlet obstruction, prostate enlargement or moderate to severe kidney impairment should discuss Yupelri carefully with a clinician. It is also not recommended for people with severe liver impairment according to the prescribing information. Anyone with a known allergy to revefenacin or product ingredients should not use it.

Can Yupelri be used with other inhalers?

Some people use more than one COPD medicine, but the combination should be directed by a clinician. Yupelri should generally not be combined with other anticholinergic medicines because side effects may increase. A pharmacist can review all inhalers, nebulizer medicines and nonprescription products for possible overlap.

What should a person do after missing a Yupelri dose?

A person should not take extra Yupelri to make up for a missed dose. They should consult the medicine guide, pharmacist or prescribing clinician for individualized instructions. Questions about dosing schedules and nebulizer use are best addressed by the healthcare professional who knows the patient’s full treatment plan.

References

• U.S. Food and Drug Administration
• DailyMed, National Library of Medicine
• Global Initiative for Chronic Obstructive Lung Disease
• American Lung Association

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.